Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019

Case Studies and Literature Review of Pneumococcal Septic Arthritis in Adults

Amandine Dernoncourt1Comments to Author , Youssef El Samad, Jean Schmidt, Jean Philippe Emond, Charlotte Gouraud, Anne Brocard, Mohamed El Hamri, Claire Plassart, Florence Rousseau, Valéry Salle, Momar Diouf, Emmanuelle Varon, and Farida Hamdad1
Author affiliations: Amiens-Picardie University Medical Center, Amiens, France (A. Dernoncourt, Y. El Samad, J. Schmidt, J.P. Emond, A. Brocard, M. El Hamri, C. Plassart, F. Rousseau, V. Salle, M. Diouf, F. Hamdad); Compiègne Hospital, Compiègne, France (J.P. Emond, C. Gouraud); Senlis Hospital, Senlis, France (A. Brocard); Laon Hospital, Laon, France (M. El Hamri); Beauvais Hospital, Beauvais, France (C. Plassart); Intercommunal Hospital of Creteil, Paris, France (E. Varon)

Main Article

Table 5

Detailed analysis of reports of septic arthritis in patients >18 years of age reported in medical literature during 1950–2019*

Study details Study authors, year published (reference)
This study Ros, et al., 2003 (10) Ispahani et al., 1999 (8) Dubost et al., 2004 (4) Raad et al., 2004 (6) James et al., 2000 (7) Belkhir et al., 2014 (9) Marrie et al., 2017 (16)
No. patients 16 11 25 7 4 14 9 51
Median age, y (IQR) 69.7 (+25) 60 (+18.5) 69 (NA) 63 (NA) 47 (+3.25) 63 (+21.75) 75 (+26) 56 (+17)
Sex, M/F
Impaired joints, no.
Knee 11 6 12 4 0 10 7 26
Hip 2 0 0 0 2 0 0 0
>1 joint 2 3 5 0 3 6 0 9
Prosthetic joint
Extraarticular infections, no. 6† 5 11 1 2 7 5 NA
Underlying conditions, no.
Known vaccination status, no. 11 0 0 0 0 0 1 0
No. immunized


Laboratory data, no. positive/no. tested
Bacteremia 11/16 9/11 20/24 4/6 1/4 8/14 5/9 51/51
Gram stain 11/14 NA 23/25 4/5 NA NA 5/9 NA
Serotypes, no. 6 1 1 NA NA NA 4 29
Strains 23B and 24F 6A 24F NA NA
Covered by PCV13
and PPV23


Penicillin S 4 3 25 NA 2 NA 5 NA
Ceftriaxone S 1 1 25 NA 1 1 NA NA
Ceftriaxone R

Median duration of antimicrobial therapy, d 42 42 49 27 49 NA 44.7 NA
Surgical intervention, no.‡
Clinical outcome
Death 1 2 8 0 0 3 1 6
Sequelae 5 4 10 4 1 2 1 NA

*IQR, interquartile range; NA, not available; PCV13, pneumococcal 13-valent conjugate vaccine; PPV23, pneumococcal 23-valent polysaccharide vaccine; R, resistant; S, susceptible.
†Data not available for all patients in study.
‡Including arthrotomy or synovectomy of affected joint or prosthetic joint replacement.

Main Article

  1. Mathews  CJ, Weston  VC, Jones  A, Field  M, Coakley  G. Bacterial septic arthritis in adults. Lancet. 2010;375:84655. DOIPubMedGoogle Scholar
  2. García-Arias  M, Balsa  A, Mola  EM. Septic arthritis. Best Pract Res Clin Rheumatol. 2011;25:40721. DOIPubMedGoogle Scholar
  3. Goldenberg  DL. Septic arthritis. Lancet. 1998;351:197202. DOIPubMedGoogle Scholar
  4. Dubost  J-J, Soubrier  M, De Champs  C, Ristori  J-M, Sauvezie  B. Streptococcal septic arthritis in adults. A study of 55 cases with a literature review. Joint Bone Spine. 2004;71:30311. DOIPubMedGoogle Scholar
  5. Ryan  MJ, Kavanagh  R, Wall  PG, Hazleman  BL. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. Br J Rheumatol. 1997;36:3703. DOIPubMedGoogle Scholar
  6. Raad  J, Peacock  JE Jr. Septic arthritis in the adult caused by Streptococcus pneumoniae: a report of 4 cases and review of the literature. Semin Arthritis Rheum. 2004;34:55969. DOIPubMedGoogle Scholar
  7. James  PA, Thomas  MG; Paul A. James, Mark G. Thomas. Streptococcus pneumoniae septic arthritis in adults. Scand J Infect Dis. 2000;32:4914. DOIPubMedGoogle Scholar
  8. Ispahani  P, Weston  VC, Turner  DP, Donald  FE. Septic arthritis due to Streptococcus pneumoniae in Nottingham, United Kingdom, 1985-1998. Clin Infect Dis. 1999;29:14504. DOIPubMedGoogle Scholar
  9. Belkhir  L, Rodriguez-Villalobos  H, Vandercam  B, Marot  JC, Cornu  O, Lambert  M, et al. Pneumococcal septic arthritis in adults: clinical analysis and review. Acta Clin Belg. 2014;69:406. DOIPubMedGoogle Scholar
  10. Ross  JJ, Saltzman  CL, Carling  P, Shapiro  DS. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis. 2003;36:31927. DOIPubMedGoogle Scholar
  11. Seng  P, Vernier  M, Gay  A, Pinelli  P-O, Legré  R, Stein  A. Clinical features and outcome of bone and joint infections with streptococcal involvement: 5-year experience of interregional reference centres in the south of France. New Microbes New Infect. 2016;12:817. DOIPubMedGoogle Scholar
  12. Dockrell  DH, Whyte  MKB, Mitchell  TJ. Pneumococcal pneumonia: mechanisms of infection and resolution. Chest. 2012;142:48291. DOIPubMedGoogle Scholar
  13. Lynch  JP III, Zhanel  GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30:189209. DOIPubMedGoogle Scholar
  14. Rueda  AM, Serpa  JA, Matloobi  M, Mushtaq  M, Musher  DM. The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore). 2010;89:3316. DOIPubMedGoogle Scholar
  15. Varon  E. Epidemiology of Streptococcus pneumoniae. Med Mal Infect. 2012;42:3615. DOIPubMedGoogle Scholar
  16. Marrie  TJ, Tyrrell  GJ, Majumdar  SR, Eurich  DT. Rates of, and risk factors for, septic arthritis in patients with invasive pneumococcal disease: prospective cohort study. BMC Infect Dis. 2017;17:680. DOIPubMedGoogle Scholar
  17. Lepoutre  A, Varon  E, Georges  S, Dorléans  F, Janoir  C, Gutmann  L, et al.; Microbiologists of Epibac; ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33:35966. DOIPubMedGoogle Scholar
  18. Webber  C, Patton  M, Patterson  S, Schmoele-Thoma  B, Huijts  SM, Bonten  MJM; CAPiTA Study Group. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017;35:126672. DOIPubMedGoogle Scholar
  19. Richard  C, Le Garlantezec  P, Lamand  V, Rasamijao  V, Rapp  C. [Anti-pneumococcal vaccine coverage for hospitalized risk patients: Assessment and suggestions for improvements]. Ann Pharm Fr. 2016;74:24451. DOIPubMedGoogle Scholar
  20. Falkenhorst  G, Remschmidt  C, Harder  T, Hummers-Pradier  E, Wichmann  O, Bogdan  C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12:e0169368. DOIPubMedGoogle Scholar
  21. Bonten  MJ, Huijts  SM, Bolkenbaas  M, Webber  C, Patterson  S, Gault  S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:111425. DOIPubMedGoogle Scholar
  22. Butler  JC, Schuchat  A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging. 1999;15(Suppl 1):119. DOIPubMedGoogle Scholar
  23. Forestier  E, Sordet  C, Cohen-Solal  J, Remy  V, Javier  RM, Kuntz  JL, et al. Bone and joint infection due to Streptococcus pneumoniae in two immunocompetent adults. Joint Bone Spine. 2006;73:3258. DOIPubMedGoogle Scholar
  24. Riachy  MA. Streptococcus pneumoniae causing septic arthritis with shock and revealing multiple myeloma. BMJ Case Rep. 2011;2011:bcr1220103664. DOIPubMedGoogle Scholar
  25. Kalambokis  GN, Christou  L, Tsianos  EV. Multiple myeloma presenting with an acute bacterial infection. Int J Lab Hematol. 2009;31:37583. DOIPubMedGoogle Scholar
  26. Bertani  A, Drouin  C, Demortière  E, Gonzalez  J-F, Candoni  P, Di Schino  M. [A prosthetic joint infection caused by Streptococcus pneumoniae: a case report and review of the literature]. Rev Chir Orthop Repar Appar Mot. 2006;92:6104. DOIPubMedGoogle Scholar
  27. Zhao  J, Zhang  S, Zhang  L, Dong  X, Li  J, Wang  Y, et al. Serum procalcitonin levels as a diagnostic marker for septic arthritis: A meta-analysis. Am J Emerg Med. 2017;35:116671. DOIPubMedGoogle Scholar
  28. Baraboutis  I, Skoutelis  A. Streptococcus pneumoniae septic arthritis in adults. Clin Microbiol Infect. 2004;10:10379. DOIPubMedGoogle Scholar
  29. Gransden  WR, Eykyn  SJ, Phillips  I. Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas’s Hospital. Br Med J (Clin Res Ed). 1985;290:5058. DOIPubMedGoogle Scholar
  30. Burman  LA, Norrby  R, Trollfors  B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis. 1985;7:13342. DOIPubMedGoogle Scholar
  31. Bhattarai  A, Nakajima  T, Sapkota  S, Arisaka  Y, Tokue  A, Yonemoto  Y, et al. Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis. Medicine (Baltimore). 2017;96:e7130. DOIPubMedGoogle Scholar
  32. van der Linden  M, Falkenhorst  G, Perniciaro  S, Imöhl  M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015;10:e0131494. DOIPubMedGoogle Scholar
  33. van der Linden  M, Perniciaro  S, Imöhl  M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015;15:207. DOIPubMedGoogle Scholar
  34. Steens  A, Bergsaker  MA, Aaberge  IS, Rønning  K, Vestrheim  DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:62328. DOIPubMedGoogle Scholar
  35. Richter  SS, Diekema  DJ, Heilmann  KP, Dohrn  CL, Riahi  F, Doern  GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58:64849. DOIPubMedGoogle Scholar
  36. Ouldali  N, Levy  C, Varon  E, Bonacorsi  S, Béchet  S, Cohen  R, et al.; French Pediatric Meningitis Network. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018;18:98391. DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this article.

Page created: September 12, 2019
Page updated: September 12, 2019
Page reviewed: September 12, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.